Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2005
10/11/2005US6953785 Estra-1,3,5(10)-triene derivatives
10/11/2005CA2341949C Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
10/06/2005WO2005093064A1 Novel galectin 9 modification protein and use thereof
10/06/2005WO2005092889A1 Composition for solid pharmaceutical preparation of solifenacin or salt thereof
10/06/2005WO2005092363A1 Preventive/remedy for diabetic complications using oligopeptide
10/06/2005WO2005092349A1 Insulin resistance improving agent
10/06/2005WO2005092321A1 Pharmaceutical composition for prevention or treatment of increased urinary frequency or involuntary urination
10/06/2005US20050222418 Novel tyloindicines and related processes, pharmaceutical compositions and methods
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222410 Inhibitors of histone deacetylase
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222249 Softgel of NLKJ for treating prostate diseases
10/06/2005US20050222201 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2)
10/06/2005US20050222194 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction
10/06/2005US20050222189 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
10/06/2005US20050222182 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
10/06/2005US20050222179 Adenosine receptor antagonists and methods of making and using the same
10/06/2005US20050222174 N-{4-[1-(2,6-difluorobenzyl)-3-(4-fluorophenyl)-5-({methy[2-(2-oxo-1-piperidinyl)ethyl]amino}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-N'-ethylurea; antagonistic action for gonadotropin-releasing hormone
10/06/2005US20050222165 Specific alpha-adrenoceptor antagonists and muscarinic antagonists are administered simultaneously, separately or sequentially to treat the lower urinary tract symptoms associated with benign prostate hyperplasia
10/06/2005US20050222162 Administering, to a patient in need of such treatment, an effective amount of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof
10/06/2005US20050222160 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone, used for inhibiting proliferation of lymphocytes in a host, and for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, arthritis, multiple sclerosis, diabetes
10/06/2005US20050222153 Tyrosine kinase enzyme inhibitors as growth factor receptors and useful as antiproliferation agents
10/06/2005US20050222139 Non-peptide gnrh antagonists
10/06/2005US20050222138 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
10/06/2005US20050222137 Combination of organic compounds
10/06/2005US20050222104 e.g. 3 beta -Formyloxy-21-acetyloxy-5-pregnen-20-one; modulate immunology response; disease associated to an excess of glucocorticoids; Cushing's syndrome, iatrogenic hypercortisolism or depression
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222025 Method of inhibiting fibrosis with a somatostatin agonist
10/06/2005US20050222024 Stabilized albumin preparations
10/06/2005US20050221483 Propagating pluripotent stem cells from monocytes; tissue engineering; cell therapy; treating cardiovascular, arteriosclerotic, metabolic and liver disorders; cell expressing albumin protein; cirrhosis of the liver
10/06/2005US20050221287 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
10/06/2005US20050220904 Pharmaceutical composition for treatment of bph and preparation thereof
10/06/2005US20050220855 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
10/06/2005US20050220784 Quinazoline derivatives as medicaments
10/06/2005CA2561696A1 Novel modified galectin 9 proteins and use thereof
10/06/2005CA2560927A1 Insulin resistance-improving agent
10/05/2005EP1582521A1 Fused furan compound
10/05/2005EP1581616A2 Novel proteins and nucleic acids encoding same
10/05/2005EP1581522A1 Flavaxate derivatives as muscarinic receptor antagonists
10/05/2005EP1581274A1 Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof
10/05/2005EP1581227A1 A method for treating renal failure
10/05/2005EP1516866A9 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
10/05/2005EP1325008B1 Piperazine derivatives
10/05/2005EP1233950B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
10/05/2005EP1202733B1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
10/05/2005EP1183233B1 Bradykinin receptor antagonists
10/05/2005CN1678626A Estrieno[3, 2-b]/[3, 4-c]pyrrole derivatives useful as modulators of the estrogen receptors
10/05/2005CN1678610A New quinuclidine amide derivatives
10/05/2005CN1678606A Novel crystals
10/05/2005CN1678585A Therapeutic agents useful for treating pain
10/05/2005CN1678575A Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
10/05/2005CN1678573A Diarylurea derivatives and their use as chloride channel blockers
10/05/2005CN1678572A Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
10/05/2005CN1678338A Method and composition for regulating the activity of regulatory T cells
10/05/2005CN1678332A Novel therapeutic use of polypodium extracts
10/05/2005CN1678320A N-biarylmethyl aminocycloalkanecarboxamide derivatives
10/05/2005CN1678317A 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(NK-1) antagonists for the treatment of emesis, depression, anxiety and cough
10/05/2005CN1678314A Glycinamide derivatives as raf-kinase inhibitors
10/05/2005CN1678301A Pasting agent
10/05/2005CN1221544C Pyrazole cyclic AMP-specific PDE inhibitors
10/05/2005CN1221534C Substited 8-arylquinoline phosphodiesterase-4 inhibitors
10/05/2005CN1221262C Phthalazine derivatives for treating inflammatory diseases
10/05/2005CN1221258C Application of bendazac lysine in the preparing process of medicine for preventing and treating diabetic nephropathy
10/05/2005CN1221254C New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
10/04/2005US6951940 Analgesics, antiinflammatory agents, antiallergens, autoimmune disease, cardiovascular disorders
10/04/2005US6951937 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
10/04/2005US6951918 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
10/04/2005US6951890 Preventing and/or treating cardiovascular disease and/or associated heart failure
10/04/2005US6951879 Heteroaromate OSC inhibitors
10/04/2005US6951876 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
10/04/2005US6951874 Compounds
10/04/2005US6951859 Anticancer agents; diseases associated with signal trans-duction pathways operating through growth factor receptors
10/04/2005US6951858 Substituted 1,2,4-triazine-3,5-diones; male and female sex hormone related conditions
10/04/2005US6951855 vascular damaging agents
10/04/2005US6951852 osteoarthritis; little to no intrinsic estrogenicity; antagonizes the effects of 17 beta -estradiol with minimal uterine stimulation; bone loss inhibitor
10/04/2005US6951850 Dipeptide derivatives
10/04/2005CA2146763C Quinolone and acridinone derivatives for the treatment of urinary incontinence
09/2005
09/29/2005WO2005090405A1 Subtype of humanized antibody against interleukin-6 receptor
09/29/2005WO2005090340A1 Piperidine-1-carboxamide derivative
09/29/2005WO2005090332A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005WO2005090285A1 Novel crystal of triterpene derivative
09/29/2005WO2005089742A1 Medicine for prevention or treatment of frequent urination or urinary incontinence
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2005089711A2 Pharmaceutical formulation containing unmilled flutamide
09/29/2005US20050215640 HMB compositions and uses thereof
09/29/2005US20050215616 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol; treating vaginal and skin atrophy
09/29/2005US20050215615 Medical compositions for intravesical treatment of bladder cancer
09/29/2005US20050215613 with indazole or thienopyrazole compounds such as 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole
09/29/2005US20050215607 Drug composition for prevention or inhibition of advance of diabetic complication
09/29/2005US20050215594 Diabetes, obesity, urogenital disorders, cardiovascular disorders, atherosclerosis; 4-[(2R)-2-(([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid for example
09/29/2005US20050215592 Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman
09/29/2005US20050215574 4-anilino quinazoline derivatives as antiproliferative agents
09/29/2005US20050215557 For therapy and prophylaxis of inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis or rheumatoid arthritis etc
09/29/2005US20050215533 Administering to mammal an effective amount of sulfaphenazole wherein the administered sulfaphenazole substantially reduces the amount of infracted tissue
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215477 Treating agonist disorderssuch asd diabetes, obesity, heart dysfunctions, AIDS-related wasting, and kidney, neurological, whole body growth disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern
09/29/2005US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214291 Treatment method
09/29/2005US20050214281 G-protein coupled receptor
1 ... 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 ... 562